Loading…

Relative involvement of globus pallidus and subthalamic nucleus in the regulation of somatodendritic dopamine release in substantia nigra is dopamine-dependent

Previously, we have shown that GABA A receptors and glutamate receptors in substantia nigra play distinct roles in the regulation of somatodendritic dopamine release. GABAergic input to substantia nigra was found to be the primary determinant of the level of spontaneous somatodendritic dopamine rele...

Full description

Saved in:
Bibliographic Details
Published in:Neuroscience 2003-01, Vol.119 (3), p.777-786
Main Authors: Cobb, W.S, Abercrombie, E.D
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c422t-168c488d62fc0832e750ef121b9f7b8101339a889f98bee0c2594474fab070763
cites cdi_FETCH-LOGICAL-c422t-168c488d62fc0832e750ef121b9f7b8101339a889f98bee0c2594474fab070763
container_end_page 786
container_issue 3
container_start_page 777
container_title Neuroscience
container_volume 119
creator Cobb, W.S
Abercrombie, E.D
description Previously, we have shown that GABA A receptors and glutamate receptors in substantia nigra play distinct roles in the regulation of somatodendritic dopamine release. GABAergic input to substantia nigra was found to be the primary determinant of the level of spontaneous somatodendritic dopamine release. In contrast, acute blockade of dopamine receptors by systemic haloperidol administration produced an increase in somatodendritic dopamine release in substantia nigra that was found to be dependent exclusively upon activation of nigral glutamate receptors. The focus of the present study was to identify anatomical structures that may participate in the differential regulation of somatodendritic dopamine release by GABA and glutamate under these two conditions. To this end, we pharmacologically inhibited the activity of either globus pallidus or subthalamic nucleus using microinfusion of the GABA A receptor agonist muscimol. The effects of these manipulations on spontaneous efflux of somatodendritic dopamine and on increases in this measure produced by systemic haloperidol administration were determined in ipsilateral substantia nigra using in vivo microdialysis. As observed previously, administration of haloperidol (0.5 mg/kg, i.p.) significantly increased extracellular dopamine in substantia nigra. Microinfusion of muscimol (400 ng/200 nl) into globus pallidus also produced a significant increase in somatodendritic dopamine efflux. When haloperidol was administered systemically in conjunction with microinfusion of muscimol into globus pallidus, an increase in nigral dopamine efflux was observed that was significantly greater than that which was produced singly by muscimol microinfusion into globus pallidus or by systemic haloperidol administration. The additive nature of the increases in somatodendritic dopamine release produced by these two manipulations indicates that independent neural circuitries may be involved. Inactivation of subthalamic nucleus by microinfusion of muscimol (200 ng/100 nl) had no effect on spontaneous somatodendritic dopamine efflux. Muscimol application into subthalamic nucleus, however, completely abolished the stimulatory effect of systemic haloperidol on dendritic dopamine efflux in substantia nigra. The present data extend our previous findings by demonstrating: 1) an important involvement of globus pallidus efferents in the GABAergic regulation of somatodendritic dopamine efflux in substantia nigra under normal conditions and, 2
doi_str_mv 10.1016/S0306-4522(03)00071-X
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_18929612</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S030645220300071X</els_id><sourcerecordid>18929612</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-168c488d62fc0832e750ef121b9f7b8101339a889f98bee0c2594474fab070763</originalsourceid><addsrcrecordid>eNqFkc2KFDEUhYMoTjv6CEo2ii5Kk1SqKlkNMvgHA4I_MLuQSm71RFJJmaQafBpf1dR0M7N0lUv4zrmXcxB6TslbSmj_7jtpSd_wjrHXpH1DCBloc_0A7agY2mboOH-IdnfIGXqS868KkY63j9EZZYLIXood-vsNvC7uANiFQ_QHmCEUHCe893FcM160987WQQeL8zqWG-317AwOq_FQ_13A5QZwgv26GcWwiXOcdYkWgk2uVNjGpYrChnnQeVu2meWiQ3EaB7dPGrt8xzUWliqupzxFjybtMzw7vefo58cPPy4_N1dfP325fH_VGM5YaWgvDBfC9mwyRLQMho7ARBkd5TSMoibWtlILIScpRgBiWCc5H_ikRzKQoW_P0auj75Li7xVyUbPLBrzXAeKaFRWSyZ6yCnZH0KSYc4JJLcnNOv1RlKitGXXbjNpiV6RVt82o66p7cVqwjjPYe9Wpigq8PAE6G-2npINx-Z7jktX9vHIXRw5qHAcHSWXjIBiwLoEpykb3n1P-AX9brmY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18929612</pqid></control><display><type>article</type><title>Relative involvement of globus pallidus and subthalamic nucleus in the regulation of somatodendritic dopamine release in substantia nigra is dopamine-dependent</title><source>ScienceDirect Freedom Collection</source><creator>Cobb, W.S ; Abercrombie, E.D</creator><creatorcontrib>Cobb, W.S ; Abercrombie, E.D</creatorcontrib><description>Previously, we have shown that GABA A receptors and glutamate receptors in substantia nigra play distinct roles in the regulation of somatodendritic dopamine release. GABAergic input to substantia nigra was found to be the primary determinant of the level of spontaneous somatodendritic dopamine release. In contrast, acute blockade of dopamine receptors by systemic haloperidol administration produced an increase in somatodendritic dopamine release in substantia nigra that was found to be dependent exclusively upon activation of nigral glutamate receptors. The focus of the present study was to identify anatomical structures that may participate in the differential regulation of somatodendritic dopamine release by GABA and glutamate under these two conditions. To this end, we pharmacologically inhibited the activity of either globus pallidus or subthalamic nucleus using microinfusion of the GABA A receptor agonist muscimol. The effects of these manipulations on spontaneous efflux of somatodendritic dopamine and on increases in this measure produced by systemic haloperidol administration were determined in ipsilateral substantia nigra using in vivo microdialysis. As observed previously, administration of haloperidol (0.5 mg/kg, i.p.) significantly increased extracellular dopamine in substantia nigra. Microinfusion of muscimol (400 ng/200 nl) into globus pallidus also produced a significant increase in somatodendritic dopamine efflux. When haloperidol was administered systemically in conjunction with microinfusion of muscimol into globus pallidus, an increase in nigral dopamine efflux was observed that was significantly greater than that which was produced singly by muscimol microinfusion into globus pallidus or by systemic haloperidol administration. The additive nature of the increases in somatodendritic dopamine release produced by these two manipulations indicates that independent neural circuitries may be involved. Inactivation of subthalamic nucleus by microinfusion of muscimol (200 ng/100 nl) had no effect on spontaneous somatodendritic dopamine efflux. Muscimol application into subthalamic nucleus, however, completely abolished the stimulatory effect of systemic haloperidol on dendritic dopamine efflux in substantia nigra. The present data extend our previous findings by demonstrating: 1) an important involvement of globus pallidus efferents in the GABAergic regulation of somatodendritic dopamine efflux in substantia nigra under normal conditions and, 2) an emergent predominant role of subthalamic nucleus efferents in the glutamate-dependent increase in somatodendritic dopamine efflux observed after systemic haloperidol administration. Thus, the relative influence of globus pallidus and subthalamic nucleus in the determination of the level of somatodendritic dopamine release in substantia nigra qualitatively varies as a function of dopamine receptor blockade. These findings are relevant to current models of basal ganglia function under both normal and pathological conditions, e.g. Parkinson's disease.</description><identifier>ISSN: 0306-4522</identifier><identifier>EISSN: 1873-7544</identifier><identifier>DOI: 10.1016/S0306-4522(03)00071-X</identifier><identifier>PMID: 12809698</identifier><identifier>CODEN: NRSCDN</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Animals ; basal ganglia ; Biological and medical sciences ; Central nervous system ; Central neurotransmission. Neuromudulation. Pathways and receptors ; Dendrites - metabolism ; Dendrites - ultrastructure ; Dopamine - metabolism ; Dopamine Antagonists - pharmacology ; Drug Synergism ; Extracellular Space - drug effects ; Extracellular Space - metabolism ; Fundamental and applied biological sciences. Psychology ; GABA ; GABA Antagonists - pharmacology ; GABA-A Receptor Antagonists ; gamma-Aminobutyric Acid - metabolism ; Globus Pallidus - cytology ; Globus Pallidus - drug effects ; Globus Pallidus - metabolism ; glutamate ; Glutamic Acid - metabolism ; Haloperidol - pharmacology ; Male ; Microdialysis ; Muscimol - pharmacology ; Neural Inhibition - drug effects ; Neural Inhibition - physiology ; Neural Pathways - cytology ; Neural Pathways - drug effects ; Neural Pathways - metabolism ; Parkinson Disease - metabolism ; Parkinson Disease - physiopathology ; Parkinson's disease ; Rats ; Rats, Sprague-Dawley ; Receptors, GABA-A - metabolism ; Substantia Nigra - cytology ; Substantia Nigra - metabolism ; Subthalamic Nucleus - cytology ; Subthalamic Nucleus - drug effects ; Subthalamic Nucleus - metabolism ; Synaptic Transmission - drug effects ; Synaptic Transmission - physiology ; Vertebrates: nervous system and sense organs</subject><ispartof>Neuroscience, 2003-01, Vol.119 (3), p.777-786</ispartof><rights>2003 IBRO</rights><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-168c488d62fc0832e750ef121b9f7b8101339a889f98bee0c2594474fab070763</citedby><cites>FETCH-LOGICAL-c422t-168c488d62fc0832e750ef121b9f7b8101339a889f98bee0c2594474fab070763</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14926124$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12809698$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cobb, W.S</creatorcontrib><creatorcontrib>Abercrombie, E.D</creatorcontrib><title>Relative involvement of globus pallidus and subthalamic nucleus in the regulation of somatodendritic dopamine release in substantia nigra is dopamine-dependent</title><title>Neuroscience</title><addtitle>Neuroscience</addtitle><description>Previously, we have shown that GABA A receptors and glutamate receptors in substantia nigra play distinct roles in the regulation of somatodendritic dopamine release. GABAergic input to substantia nigra was found to be the primary determinant of the level of spontaneous somatodendritic dopamine release. In contrast, acute blockade of dopamine receptors by systemic haloperidol administration produced an increase in somatodendritic dopamine release in substantia nigra that was found to be dependent exclusively upon activation of nigral glutamate receptors. The focus of the present study was to identify anatomical structures that may participate in the differential regulation of somatodendritic dopamine release by GABA and glutamate under these two conditions. To this end, we pharmacologically inhibited the activity of either globus pallidus or subthalamic nucleus using microinfusion of the GABA A receptor agonist muscimol. The effects of these manipulations on spontaneous efflux of somatodendritic dopamine and on increases in this measure produced by systemic haloperidol administration were determined in ipsilateral substantia nigra using in vivo microdialysis. As observed previously, administration of haloperidol (0.5 mg/kg, i.p.) significantly increased extracellular dopamine in substantia nigra. Microinfusion of muscimol (400 ng/200 nl) into globus pallidus also produced a significant increase in somatodendritic dopamine efflux. When haloperidol was administered systemically in conjunction with microinfusion of muscimol into globus pallidus, an increase in nigral dopamine efflux was observed that was significantly greater than that which was produced singly by muscimol microinfusion into globus pallidus or by systemic haloperidol administration. The additive nature of the increases in somatodendritic dopamine release produced by these two manipulations indicates that independent neural circuitries may be involved. Inactivation of subthalamic nucleus by microinfusion of muscimol (200 ng/100 nl) had no effect on spontaneous somatodendritic dopamine efflux. Muscimol application into subthalamic nucleus, however, completely abolished the stimulatory effect of systemic haloperidol on dendritic dopamine efflux in substantia nigra. The present data extend our previous findings by demonstrating: 1) an important involvement of globus pallidus efferents in the GABAergic regulation of somatodendritic dopamine efflux in substantia nigra under normal conditions and, 2) an emergent predominant role of subthalamic nucleus efferents in the glutamate-dependent increase in somatodendritic dopamine efflux observed after systemic haloperidol administration. Thus, the relative influence of globus pallidus and subthalamic nucleus in the determination of the level of somatodendritic dopamine release in substantia nigra qualitatively varies as a function of dopamine receptor blockade. These findings are relevant to current models of basal ganglia function under both normal and pathological conditions, e.g. Parkinson's disease.</description><subject>Animals</subject><subject>basal ganglia</subject><subject>Biological and medical sciences</subject><subject>Central nervous system</subject><subject>Central neurotransmission. Neuromudulation. Pathways and receptors</subject><subject>Dendrites - metabolism</subject><subject>Dendrites - ultrastructure</subject><subject>Dopamine - metabolism</subject><subject>Dopamine Antagonists - pharmacology</subject><subject>Drug Synergism</subject><subject>Extracellular Space - drug effects</subject><subject>Extracellular Space - metabolism</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>GABA</subject><subject>GABA Antagonists - pharmacology</subject><subject>GABA-A Receptor Antagonists</subject><subject>gamma-Aminobutyric Acid - metabolism</subject><subject>Globus Pallidus - cytology</subject><subject>Globus Pallidus - drug effects</subject><subject>Globus Pallidus - metabolism</subject><subject>glutamate</subject><subject>Glutamic Acid - metabolism</subject><subject>Haloperidol - pharmacology</subject><subject>Male</subject><subject>Microdialysis</subject><subject>Muscimol - pharmacology</subject><subject>Neural Inhibition - drug effects</subject><subject>Neural Inhibition - physiology</subject><subject>Neural Pathways - cytology</subject><subject>Neural Pathways - drug effects</subject><subject>Neural Pathways - metabolism</subject><subject>Parkinson Disease - metabolism</subject><subject>Parkinson Disease - physiopathology</subject><subject>Parkinson's disease</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Receptors, GABA-A - metabolism</subject><subject>Substantia Nigra - cytology</subject><subject>Substantia Nigra - metabolism</subject><subject>Subthalamic Nucleus - cytology</subject><subject>Subthalamic Nucleus - drug effects</subject><subject>Subthalamic Nucleus - metabolism</subject><subject>Synaptic Transmission - drug effects</subject><subject>Synaptic Transmission - physiology</subject><subject>Vertebrates: nervous system and sense organs</subject><issn>0306-4522</issn><issn>1873-7544</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNqFkc2KFDEUhYMoTjv6CEo2ii5Kk1SqKlkNMvgHA4I_MLuQSm71RFJJmaQafBpf1dR0M7N0lUv4zrmXcxB6TslbSmj_7jtpSd_wjrHXpH1DCBloc_0A7agY2mboOH-IdnfIGXqS868KkY63j9EZZYLIXood-vsNvC7uANiFQ_QHmCEUHCe893FcM160987WQQeL8zqWG-317AwOq_FQ_13A5QZwgv26GcWwiXOcdYkWgk2uVNjGpYrChnnQeVu2meWiQ3EaB7dPGrt8xzUWliqupzxFjybtMzw7vefo58cPPy4_N1dfP325fH_VGM5YaWgvDBfC9mwyRLQMho7ARBkd5TSMoibWtlILIScpRgBiWCc5H_ikRzKQoW_P0auj75Li7xVyUbPLBrzXAeKaFRWSyZ6yCnZH0KSYc4JJLcnNOv1RlKitGXXbjNpiV6RVt82o66p7cVqwjjPYe9Wpigq8PAE6G-2npINx-Z7jktX9vHIXRw5qHAcHSWXjIBiwLoEpykb3n1P-AX9brmY</recordid><startdate>20030101</startdate><enddate>20030101</enddate><creator>Cobb, W.S</creator><creator>Abercrombie, E.D</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>20030101</creationdate><title>Relative involvement of globus pallidus and subthalamic nucleus in the regulation of somatodendritic dopamine release in substantia nigra is dopamine-dependent</title><author>Cobb, W.S ; Abercrombie, E.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-168c488d62fc0832e750ef121b9f7b8101339a889f98bee0c2594474fab070763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Animals</topic><topic>basal ganglia</topic><topic>Biological and medical sciences</topic><topic>Central nervous system</topic><topic>Central neurotransmission. Neuromudulation. Pathways and receptors</topic><topic>Dendrites - metabolism</topic><topic>Dendrites - ultrastructure</topic><topic>Dopamine - metabolism</topic><topic>Dopamine Antagonists - pharmacology</topic><topic>Drug Synergism</topic><topic>Extracellular Space - drug effects</topic><topic>Extracellular Space - metabolism</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>GABA</topic><topic>GABA Antagonists - pharmacology</topic><topic>GABA-A Receptor Antagonists</topic><topic>gamma-Aminobutyric Acid - metabolism</topic><topic>Globus Pallidus - cytology</topic><topic>Globus Pallidus - drug effects</topic><topic>Globus Pallidus - metabolism</topic><topic>glutamate</topic><topic>Glutamic Acid - metabolism</topic><topic>Haloperidol - pharmacology</topic><topic>Male</topic><topic>Microdialysis</topic><topic>Muscimol - pharmacology</topic><topic>Neural Inhibition - drug effects</topic><topic>Neural Inhibition - physiology</topic><topic>Neural Pathways - cytology</topic><topic>Neural Pathways - drug effects</topic><topic>Neural Pathways - metabolism</topic><topic>Parkinson Disease - metabolism</topic><topic>Parkinson Disease - physiopathology</topic><topic>Parkinson's disease</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Receptors, GABA-A - metabolism</topic><topic>Substantia Nigra - cytology</topic><topic>Substantia Nigra - metabolism</topic><topic>Subthalamic Nucleus - cytology</topic><topic>Subthalamic Nucleus - drug effects</topic><topic>Subthalamic Nucleus - metabolism</topic><topic>Synaptic Transmission - drug effects</topic><topic>Synaptic Transmission - physiology</topic><topic>Vertebrates: nervous system and sense organs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cobb, W.S</creatorcontrib><creatorcontrib>Abercrombie, E.D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cobb, W.S</au><au>Abercrombie, E.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relative involvement of globus pallidus and subthalamic nucleus in the regulation of somatodendritic dopamine release in substantia nigra is dopamine-dependent</atitle><jtitle>Neuroscience</jtitle><addtitle>Neuroscience</addtitle><date>2003-01-01</date><risdate>2003</risdate><volume>119</volume><issue>3</issue><spage>777</spage><epage>786</epage><pages>777-786</pages><issn>0306-4522</issn><eissn>1873-7544</eissn><coden>NRSCDN</coden><abstract>Previously, we have shown that GABA A receptors and glutamate receptors in substantia nigra play distinct roles in the regulation of somatodendritic dopamine release. GABAergic input to substantia nigra was found to be the primary determinant of the level of spontaneous somatodendritic dopamine release. In contrast, acute blockade of dopamine receptors by systemic haloperidol administration produced an increase in somatodendritic dopamine release in substantia nigra that was found to be dependent exclusively upon activation of nigral glutamate receptors. The focus of the present study was to identify anatomical structures that may participate in the differential regulation of somatodendritic dopamine release by GABA and glutamate under these two conditions. To this end, we pharmacologically inhibited the activity of either globus pallidus or subthalamic nucleus using microinfusion of the GABA A receptor agonist muscimol. The effects of these manipulations on spontaneous efflux of somatodendritic dopamine and on increases in this measure produced by systemic haloperidol administration were determined in ipsilateral substantia nigra using in vivo microdialysis. As observed previously, administration of haloperidol (0.5 mg/kg, i.p.) significantly increased extracellular dopamine in substantia nigra. Microinfusion of muscimol (400 ng/200 nl) into globus pallidus also produced a significant increase in somatodendritic dopamine efflux. When haloperidol was administered systemically in conjunction with microinfusion of muscimol into globus pallidus, an increase in nigral dopamine efflux was observed that was significantly greater than that which was produced singly by muscimol microinfusion into globus pallidus or by systemic haloperidol administration. The additive nature of the increases in somatodendritic dopamine release produced by these two manipulations indicates that independent neural circuitries may be involved. Inactivation of subthalamic nucleus by microinfusion of muscimol (200 ng/100 nl) had no effect on spontaneous somatodendritic dopamine efflux. Muscimol application into subthalamic nucleus, however, completely abolished the stimulatory effect of systemic haloperidol on dendritic dopamine efflux in substantia nigra. The present data extend our previous findings by demonstrating: 1) an important involvement of globus pallidus efferents in the GABAergic regulation of somatodendritic dopamine efflux in substantia nigra under normal conditions and, 2) an emergent predominant role of subthalamic nucleus efferents in the glutamate-dependent increase in somatodendritic dopamine efflux observed after systemic haloperidol administration. Thus, the relative influence of globus pallidus and subthalamic nucleus in the determination of the level of somatodendritic dopamine release in substantia nigra qualitatively varies as a function of dopamine receptor blockade. These findings are relevant to current models of basal ganglia function under both normal and pathological conditions, e.g. Parkinson's disease.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>12809698</pmid><doi>10.1016/S0306-4522(03)00071-X</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0306-4522
ispartof Neuroscience, 2003-01, Vol.119 (3), p.777-786
issn 0306-4522
1873-7544
language eng
recordid cdi_proquest_miscellaneous_18929612
source ScienceDirect Freedom Collection
subjects Animals
basal ganglia
Biological and medical sciences
Central nervous system
Central neurotransmission. Neuromudulation. Pathways and receptors
Dendrites - metabolism
Dendrites - ultrastructure
Dopamine - metabolism
Dopamine Antagonists - pharmacology
Drug Synergism
Extracellular Space - drug effects
Extracellular Space - metabolism
Fundamental and applied biological sciences. Psychology
GABA
GABA Antagonists - pharmacology
GABA-A Receptor Antagonists
gamma-Aminobutyric Acid - metabolism
Globus Pallidus - cytology
Globus Pallidus - drug effects
Globus Pallidus - metabolism
glutamate
Glutamic Acid - metabolism
Haloperidol - pharmacology
Male
Microdialysis
Muscimol - pharmacology
Neural Inhibition - drug effects
Neural Inhibition - physiology
Neural Pathways - cytology
Neural Pathways - drug effects
Neural Pathways - metabolism
Parkinson Disease - metabolism
Parkinson Disease - physiopathology
Parkinson's disease
Rats
Rats, Sprague-Dawley
Receptors, GABA-A - metabolism
Substantia Nigra - cytology
Substantia Nigra - metabolism
Subthalamic Nucleus - cytology
Subthalamic Nucleus - drug effects
Subthalamic Nucleus - metabolism
Synaptic Transmission - drug effects
Synaptic Transmission - physiology
Vertebrates: nervous system and sense organs
title Relative involvement of globus pallidus and subthalamic nucleus in the regulation of somatodendritic dopamine release in substantia nigra is dopamine-dependent
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T07%3A00%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relative%20involvement%20of%20globus%20pallidus%20and%20subthalamic%20nucleus%20in%20the%20regulation%20of%20somatodendritic%20dopamine%20release%20in%20substantia%20nigra%20is%20dopamine-dependent&rft.jtitle=Neuroscience&rft.au=Cobb,%20W.S&rft.date=2003-01-01&rft.volume=119&rft.issue=3&rft.spage=777&rft.epage=786&rft.pages=777-786&rft.issn=0306-4522&rft.eissn=1873-7544&rft.coden=NRSCDN&rft_id=info:doi/10.1016/S0306-4522(03)00071-X&rft_dat=%3Cproquest_cross%3E18929612%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c422t-168c488d62fc0832e750ef121b9f7b8101339a889f98bee0c2594474fab070763%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=18929612&rft_id=info:pmid/12809698&rfr_iscdi=true